Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

First Quarter 2025

First quarter 2025 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.

Thursday April 24, 2025
13:00 - 14:30 CEST (7:00am – 8:30am EDT)

Press Releases


April 18, 2025
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

April 15, 2025
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

April 8, 2025
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Upcoming Events

24Apr

2025

First quarter 2025

First quarter 2025 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.

13:00 - 14:30 CEST (7:00am – 8:30am EDT)

Quarterly results

Discover more

30Apr

2025

Annual General Meeting 2025

The Sanofi General Meeting will be held on April 30, 2025 at the Palais des Congrès in Paris, Porte Maillot. It will be live video webcasted.

14:30 - 16:30

Annual general meetings

Discover more

14May

2025

Redburn Atlantic Canada Conference

08:00 Canada

Conferences


Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing
Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

Dividend Increase

Expected for the 30th consecutive year​, submitted to the annual general meeting vote on April 30th, 2025.

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00